41 results about "Animals vaccines" patented technology

This utility model relates to the field of medical equipment technology, and in particular to an animal vaccine injection booster device, comprising a first air chamber, a second air chamber, a piston assembly, and a gun body; the gun body has a first air chamber and a second air chamber, the first air chamber having a gas source inlet, a gas outlet, and a gas delivery outlet, the gas delivery outlet communicating with the second air chamber, and a control valve also being provided in the first air chamber; when the trigger of the gun body presses the control valve, the control valve blocks the connection between the gas delivery outlet and the gas outlet; when the trigger of the gun body is released, the control valve blocks the connection between the gas delivery outlet and the gas source inlet; the second air chamber has a piston assembly, the piston assembly including a piston and a firing pin, the firing pin being disposed on the piston, and an elastic element being provided between the piston and the firing pin output end of the second air chamber; the trigger is disposed on the grip part of the gun body, the grip part having a grip groove on the side near the trigger, and a thumb groove on the top side of the grip part away from the trigger. This utility model is easy to operate and has a good grip feel.

The application provides a preparation method of polysaccharide vaccine diluent and application to chicken newcastle disease vaccine, and belongs to the technical field of biopharmacy.The application provides a south five canes polysaccharide vaccine diluent and a preparation method thereof, and solves the problems of low uniformity of antibody titer, stress reaction and allergic reaction of the body after inoculation, and influence on the immunization effect of the vaccine caused by the physiological saline or the phosphate buffer solution diluent for diluting the vaccine.The south five canes polysaccharide vaccine diluent can be applied to animal vaccines, including chicken newcastle disease vaccine, and solves the problem that there is no polysaccharide diluent for the chicken newcastle disease vaccine in the prior art.

1. Name of the product in this design: Animal vaccination station (for veterinary use). 2. Purpose of this design: For vaccinating animals. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The application relates to the technical field of biological medicine, and particularly discloses CpG oligodeoxynucleotides and application thereof. The CpG oligodeoxynucleotide has a sequence as shown in any one of SEQ ID NO. 3-6, 9, and preferably has a sequence as shown in SEQ ID NO. 3-6. The CpG oligodeoxynucleotide can effectively activate the immune system of a human body or an animal, has the functions of preventing and treating pathogenic microorganism infection in a broad spectrum, has the function of improving the immunogenicity of a common vaccine, and can be applied as a human or animal vaccine adjuvant.

The invention discloses a bovine virus diarrhea live vaccine based on suspension culture and a preparation method thereof, and relates to the field of animal vaccines. The bovine viral diarrhea virus vaccine is a freeze-dried vaccine, and each vaccine contains a bovine viral diarrhea virus BVDV attenuated strain antigen and a freeze-drying protective agent; wherein the virus content of the antigen of the BVDV attenuated strain is 105-107 CCID50 / piece, and the BVDV attenuated strain is a cytopathic effect type attenuated strain suitable for suspension culture; the freeze-drying protective agent comprises trehalose, cane sugar, gelatin hydrolysate, sodium glutamate and polyvinylpyrrolidone. The suspension culture technology is adopted, large-scale, efficient and stable production of BVDV antigens is achieved, an optimized freeze-drying formula is combined, the obtained vaccine is high in virus titer, good in immunogenicity, high in stability, good in safety, advanced in production process, controllable in cost and suitable for industrial large-scale production.

The application discloses a production method and a production system of white oil for animal vaccines, and the production method is characterized in that: firstly, raw materials are cut and separated to obtain light components and heavy components; the heavy components enter an adsorption-isomerization reaction unit to be in contact with a catalyst, and after treatment, a material flow A is obtained; when the refractive index of the material flow A is higher than that of the heavy components, the heavy components stop entering the adsorption-isomerization reaction unit; hydrogen is introduced into the adsorption-isomerization reaction unit to generate an isomerization condensation reaction, and the reaction product is further subjected to a hydrogenation refining reaction; after the reaction effluent is separated, a gas phase product, light white oil and white oil for animal vaccines are obtained. According to the method, non-ideal components are separated in advance, so that the isomerization condensation reaction is only performed on raw materials rich in ideal components, hydrogenation refining and isomerization condensation processing loads are reduced, hydrogen consumption in the process is reduced, and the economic efficiency of the device is improved.

The application belongs to the technical field of animal vaccines, and particularly relates to an O-A-Dex-Ap for African swine fever immunization. Based on the good biocompatibility of Dextran, the application uses the Dextran as a nanoparticle to load a coupled CTL epitope peptide. Preliminary experimental results show that, compared with the epitope peptide alone, the O-A-Dex-Ap after loading and coupling can more effectively promote antigen presentation and activate more persistent CTL immune response, and has good application potential. Based on the results, a good technical foundation can be laid for subsequent preparation of African swine fever and other disease vaccines.

The invention discloses application of CpG ODN in preparation of a medicine for regulating animal immune cell activity, and relates to the technical field of animal vaccines. In the invention, the regulation of the animal immune cell activity is to promote the immune response reaction of immune cells; the step of promoting the immune response reaction of the immune cells comprises the step of promoting the immune cells to generate interferon. The CpG ODN provided by the invention can well and specifically stimulate immune cells of animals, especially pigs to release cytokines and promote the animals to generate rapid and strong immune response to immunogens; when being applied to an animal vaccine, the vaccine can stimulate animals to generate a higher antibody level in a shorter time, and can maintain the high-level antibody for a long time, and the immunogenicity of the vaccine is remarkably improved.

The present application relates to the technical field of biological medicine, in particular to a kind of mRNA vaccine for obtaining bovine nodular skin disease virus neutralizing antibody and application thereof.The mRNA vaccine, characterized in that, contain A27L antigen selected fragment, or L1R antigen selected fragment.The mRNA vaccine provided by the present application successfully induced effective immune response in mice and cattle, detected high level of serum neutralization titer, and the effect is better than goatpox live vaccine (CVCC AV41) vaccine, and the antibody induced has no antibody-dependent enhancement effect.This breakthrough fills the blank in the current LSDV vaccine research and development field, provides a new solution for the production and research and development of animal vaccine, and has very high commercial value and broad application prospect.

The utility model relates to the technical field of animal medical treatment, and discloses an angle-adjustable animal vaccine injection auxiliary device which comprises a bottom plate and an upper plate, the upper plate is arranged right above the bottom plate, a sleeve is fixed above the bottom plate, a supporting rod is arranged in the sleeve in a sliding mode, one end of the supporting rod penetrates through the sleeve and is connected to the bottom of the upper plate in a rotating mode, and the other end of the supporting rod is connected to the lower portion of the upper plate. A limiting mechanism is arranged between the supporting rod and the sleeve, an adjusting mechanism is connected between one side of the upper portion of the supporting rod and the upper plate, and a clamping mechanism is arranged above the upper plate. An operator firstly places the device at a proper position close to an animal to be injected, and the height of the device can be adjusted by adjusting the height of the supporting rod, so that the height of the device can be adjusted according to rough heights of animals with different heights and different parts.

The invention discloses a recombinant duck enteritis virus for expressing 3-type duck hepatitis A virus immunogenic genes and a construction method and application thereof. The recombinant duck enteritis virus is characterized in that an eukaryotic expression cassette containing a type 3 duck hepatitis A virus immunogenic gene is inserted into a non-coding region between UL26 and USL27 genes of a duck enteritis virus genome. According to the invention, a duck hepatitis A virus (DHAV) immunogenic gene is inserted into a duck enteritis virus (DEV) genome at a fixed point by virtue of a CRISPR / Cas9 gene editing technology, so that the recombinant duck enteritis virus for expressing the duck hepatitis A virus type 3 immunogenic gene is constructed and obtained. Moreover, based on the recombinant duck enteritis virus for expressing the 3-type duck hepatitis A virus immunogenicity gene constructed by the invention, the exogenous DHAV immunogenicity gene can be stably expressed in the recombinant virus, and the recombinant virus has good in-vitro replication ability and hereditary stability and can be used for preparing animal vaccines.

The invention discloses a bovine virus diarrhea and rhinotracheitis bivalent inactivated vaccine and a preparation method thereof, and relates to the field of animal vaccines. The composition is prepared from the following components in parts by volume: 40-50 parts of a water phase and 50-60 parts of an oil phase, the water phase comprises a bovine viral diarrhea virus antigen solution, an infectious bovine rhinotracheitis virus antigen solution, a stabilizer, a preservative and a phosphate buffer solution; the oil phase is prepared from white oil, span-80 and tween-80. The invention adopts BPL to inactivate BVDV and formaldehyde to inactivate IBRV, the inactivation process is designed according to virus characteristics, the inactivation is thorough, the safety is high, the immunogenicity of the virus can be retained to the greatest extent, the vaccine formula is scientific, and the physical and chemical stability of the vaccine during the storage period is improved by adopting the compound stabilizer.

The utility model relates to the field of animal vaccine immunization, in particular to a portable vaccine dilution operation table which comprises a sealing bin, a transparent partition plate fixedly installed at the upper end of the sealing bin, a sealing door arranged on the front side of the sealing bin, a sealing operation glove arranged on the inner side of the sealing bin and an operation platform arranged at the lower end of the sealing bin. Self-locking universal wheels are arranged at the lower end of the operating platform, a vertical plate is arranged at the upper end of the operating platform, an illuminating lamp is fixedly installed on the front side of the vertical plate, a sprayer is arranged below the illuminating lamp, a disinfectant box is arranged on the rear side of the vertical plate, a filter box is arranged at the upper end of the rear side of the vertical plate, and a sealing cover is arranged on the rear side of the filter box. According to the utility model, the sealed operation glove is used for operation in the sealed bin, potential biological safety hazards such as vaccine spilling and aerosol diffusion are effectively avoided, and the biological safety risk is further reduced by spraying and disinfecting articles in the sealed bin through the sprayer, ventilating the sealed bin through the fan and filtering airflow through the filter element.

The animal vaccine intelligent constant-temperature preservation box comprises a preservation box body, constant-temperature refrigeration equipment is fixedly installed at the bottom of an inner cavity of the preservation box body, a refrigeration pipe is fixedly installed at the output end of the top of the constant-temperature refrigeration equipment, and a columnar visual heat preservation bin is arranged at the top of the constant-temperature refrigeration equipment in an embedded and sliding mode; a movable groove is formed in the middle of an inner cavity of the heat preservation bin, a plurality of heat preservation chambers are formed in the heat preservation bin, a through hole is formed between each heat preservation chamber and the movable groove, and refrigeration air enters the independent heat preservation chambers through the through holes, so that the vaccine tubes in the heat preservation chambers are refrigerated, and when a worker independently takes out the vaccine tubes, the vaccine tubes in the heat preservation chambers can be conveniently taken out. The sealing door can be pulled through the locking mechanism, so that a vaccine tube in the independent heat preservation chamber can be taken out and put in, the overall refrigeration effect of overall refrigeration air cannot be affected by leakage of the independent heat preservation chamber, and the constant-temperature preservation effect on vaccines is improved.

The invention belongs to the technical field of animal breeding, and particularly relates to an animal vaccination device which comprises a medicine box, a positioning frame is fixed to the bottom end of the medicine box, a medicine pumping pipe is arranged in the positioning frame, a needle is mounted at the bottom end of the medicine pumping pipe, a piston is arranged in the medicine pumping pipe, a push rod is fixed to the top end of the piston, and a movable hole is formed in the middle of the medicine box. Fixing plates are fixed to the two sides of the interior of the movable hole, lifting rods are fixed to the two sides of the top end of the pesticide pumping pipe, a lifting plate is fixed to the middles of the lifting rods, first springs are fixed to the top end of the lifting plate, the top ends of the first springs are fixedly connected with the bottom ends of the fixing plates, and a trigger assembly is arranged below the lifting plate; the needle head is positioned through the positioning frame, then the push plate is pressed to drive the clamping plate to be separated from the lifting plate, so that the first spring is released to drive the lifting rod, the lifting rod drives the needle head to be quickly inserted into an animal body, the animal positioning time is shortened, and the inoculation efficiency can be improved.

The application belongs to the technical field of animal vaccine preparation, and discloses an African swine fever virus (ASFV) multi-epitope fusion protein, a ferritin nanoparticle vaccine of the ASFV multi-epitope fusion protein and application. The application obtains 16 dominant B cell epitopes by using an ASFV phage display library in combination with reverse screening of clinical positive serum, and constructs a nanoparticle vaccine by linking the 16 epitopes with ferritin self-assembly. The vaccine has excellent biosafety, can induce high-level and sustained specific antibodies and significant IFN-gamma cellular immune response in pigs, can effectively delay the clinical onset and death process of pigs in ASFV virulent challenge experiments, and can significantly reduce the virus load in whole-body organ tissues, thereby providing 25% survival protection rate. The application provides an effective new strategy for the development of a subunit vaccine for responding to various ASFV mutant strains.

The invention belongs to the technical field of animal vaccine diluting devices, and particularly relates to a diluting device and method for preparing animal vaccine.The device comprises a stirring barrel, the top of the stirring barrel is communicated with a first feeding part and a second feeding part, a ventilation stirring part is arranged in the middle of the inner side of the stirring barrel, and the air inlet end of the ventilation stirring part is communicated with an air supply assembly; the air outlet end of the ventilation stirring part is communicated with the interior of the stirring barrel, the stirring barrel is communicated with the air inlet end of a filter, and the air outlet end of the filter is communicated with one air inlet end of an air supply assembly through a reversing valve; the ventilation stirring part comprises a hollow rotating pipe rotationally arranged at the axis of the inner side of the stirring barrel, the bottom end of the hollow rotating pipe communicates with the air outlet end of the air supply assembly, a plurality of stirring pipes are arranged on the hollow rotating pipe in a matrix surrounding mode, the stirring pipes communicate with the hollow rotating pipe, and a plurality of air holes formed in rows are formed in the stirring pipes; the axis of the air hole is horizontally arranged. The invention further discloses a using method of the device.

The invention provides a polymer composite adjuvant for an animal vaccine and a preparation method thereof, and the polymer composite adjuvant for the animal vaccine comprises acrylate hydrogel, nano oil emulsion and an immunopotentiator, the acrylate hydrogel is prepared by the following steps: generating a polyacrylate precipitate from an acrylic hydrophilic monomer and an acrylic hydrophobic monomer in a solvent by adopting a precipitation polymerization method, and immersing the precipitate in ultrapure water, the hydrophilic monomer is one of acrylic acid and methacrylic acid, and the hydrophobic monomer is acrylate with the carbon chain length of 10-22; the immunopotentiator is a TLR3 (toll-like receptor 3) or TLR9 (toll-like The polymer composite adjuvant disclosed by the invention has good biocompatibility, low mineral oil content and small side effects, not only can play an antigen slow release role, but also can improve the cellular immune response of an organism, has the average particle size of 40-60 nm, and is good in dispersity, and a prepared vaccine is low in viscosity and easy to inject; and the preparation process is simple, the stability is high, and the biological safety is good.

The invention provides a preparation method and application of recombinant staphylococcus aureus leukocidin E. The preparation method comprises fine purification, wherein the fine purification comprises a first step of purification, a second step of desalination replacement, a third step of purification and a fourth step of purification. The recombinant staphylococcus aureus leukocidin E prepared by the invention not only meets the quality standard required by pharmacopeia, but also has the advantages of simple process, high yield, easiness in amplification and low cost, and has wide application prospects in preparation of human vaccines, veterinary vaccines and antibody drugs and development of in-vitro diagnostic reagents.

The invention belongs to the technical field of animal vaccine production, and provides a dispensing device for animal vaccine production, which comprises a tank body, the top of the tank body is provided with an isolation cabin, the isolation cabin is internally provided with a disinfection assembly, the top of the tank body is communicated with a liquid inlet pipe, the liquid inlet pipe is located in the isolation cabin, and the isolation cabin is internally provided with a plurality of quantitative liquid outlet pipe assemblies. The liquid outlet ends of the quantitative liquid outlet pipe assemblies are positioned above the liquid inlet pipe; the anti-dripping assembly comprises a bearing disc arranged in the isolation cabin and a piston connected in the quantitative liquid outlet pipe assembly in a sliding mode, a driving mechanism is arranged in the isolation cabin and used for driving the piston to move towards the liquid outlet end of the quantitative liquid outlet pipe, a pop-up mechanism is arranged between the bearing disc and the driving mechanism, and when the piston finishes moving, the pop-up mechanism can pop up the liquid outlet end of the quantitative liquid outlet pipe. And the ejecting mechanism is used for ejecting the receiving disc to the position below the quantitative liquid outlet pipe assemblies. The device can be used for producing and dispensing animal vaccines in a high-precision and sterile manner, and can adapt to the viscous characteristics of various materials.

The invention belongs to the technical field of animal vaccine preparation, and discloses an African swine fever virus multi-epitope fusion protein and a ferritin nanoparticle vaccine and application thereof. According to the invention, an ASFV phage display library is combined with clinical positive serum reverse screening to obtain 16 dominant B cell epitopes, and the 16 epitopes are connected in series with an epitope and are self-assembled with ferritin to construct the nanoparticle vaccine. The vaccine has excellent biological safety; a high-level and continuous specific antibody and remarkable IFN-gamma cellular immune response can be induced and generated in a pig body; in an ASFV virulent virus challenge experiment, the vaccine can effectively delay clinical morbidity and death processes of pigs, remarkably reduce virus load in visceral organ tissues of the whole body and provide a survival protection rate of 25%. The invention provides an effective new strategy for research and development of subunit vaccines for coping with ASFV multi-variant strains.

Provided are a Mycoplasma hyopneumoniae subunit vaccine, a preparation method therefor, and use thereof, which belong to the field of animal vaccines. The Mycoplasma hyopneumoniae subunit vaccine uses a Mycoplasma hyopneumoniae fusion protein as an antigen, the amino acid sequence of which is set forth in SEQ ID NO: 1. The preparation method comprises the following steps: (1) preparing an aqueous phase containing the fusion protein; and (2) mixing an oil phase and the aqueous phase according to a volume ratio of 1:0.8-1.2, and emulsifying to obtain the vaccine. The Mycoplasma hyopneumoniae subunit vaccine can protect pigs effectively for a long time and provides an effective means for the prevention and control of Mycoplasma hyopneumoniae.

The application provides a kind of composite nano adjuvant preparation based on zirconium metal organic framework and its application in animal vaccine.The nano adjuvant preparation includes zirconium metal organic framework material and one or more polymers, and the mass ratio of the porous zirconium metal organic framework material to the polymer is 1:1-3.The composite nano adjuvant preparation based on zirconium metal organic framework provided by the application has good stability and safety, can effectively enhance immune response and attack protection effect, and can be widely used in the preparation of animal inactivated vaccine, attenuated vaccine, recombinant protein vaccine, polypeptide vaccine and nucleic acid vaccine.The composite adjuvant preparation has low cost, simple preparation process and easy scale production.

Animal vaccine spraying equipment comprises a conveying mechanism, a liquid medicine box and a spraying mechanism, a belt type conveying mechanism comprises a transmission device and a conveying belt, a plurality of limiting clamping plate sets are arranged on the conveying belt in the moving direction of the conveying belt, each limiting clamping plate set comprises three limiting clamping plates arranged at different intervals, and the limiting clamping plates are arranged on the conveying belt. Wherein the first distance between every two adjacent limiting clamping plates is equal to the length of the baby chick frame, and the second distance is smaller than the length of the baby chick frame; the two groups of spraying mechanisms are respectively communicated with two ports of the liquid medicine box and are arranged on the two sides of the conveying belt in a staggered manner; the liquid medicine box is arranged at one end of the conveying mechanism, and a stirring device is arranged in the liquid medicine box. Each baby chick frame can be fully immunized, the immunization efficiency is improved, the device has an easy backup function, and the loss caused by shutdown maintenance of the device is reduced.

1. The name of the design product: continuous syringe. 2. The use of the design product: continuous injection for animal vaccine. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

This document provides methods and materials relating to isolated polypeptides, polypeptide preparations, vaccine preparations (e.g., anti-cancer vaccine preparations), and methods for vaccinating mammals. For example, polypeptides (e.g., CMV, MUC1, HER2, Mesothelin (MESO), TRAG-3, or CALR polypeptides) having the ability to be processed into different polypeptides such that the processed polypeptides as a group are capable of being presented by different MHC molecules present in a particular mammalian population are provided.

The invention relates to an application of an activity regulating cytoskeleton associated protein (ARC) in an REV nanoparticle vaccine and the vaccine, and belongs to the technical field of animal vaccine preparation, the amino acid sequence of the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3, the nucleotide sequence is shown as SEQ ID NO.4, and the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3. The activity regulation cytoskeleton associated protein is used as a carrier protein in a nanoparticle vaccine, and the nanoparticle vaccine is an REV nanoparticle vaccine. The ARC is used as a carrier in the nanoparticle vaccine for the first time to be self-assembled into nanoparticles, and the nanoparticles can serve as an antigen delivery platform, play a protein-antigen delivery role and stimulate an organism to generate immune response.

The invention provides an adjuvant for an oil-in-water animal vaccine. The adjuvant contains 8.8%-19.6% of mineral oil, 3.7%-6.6% of span 80, 6.1%-11.0% of Tween 80, 3.9%-7.0% of glycerol, 2.9%-5.3% of polyglycerol ester and the balance of water for injection, wherein the total percentage of the adjuvant is 100%. The oil-in-water adjuvant disclosed by the invention is simple in formula and simple in preparation method; the animal vaccine prepared by utilizing the adjuvant is good in physical stability, can be stored for more than 12 months at 4 DEG C, can be stored for 12 months at 25 DEG C and can be stored for 2 months at 37 DEG C, and the storage stability is obviously superior to that of similar products at home and abroad; the animal vaccine prepared from the adjuvant is low in viscosity and easy to inject, no visible residue exists in animal experiments, death or obvious adverse reaction caused by vaccine injection is avoided, and guarantee is provided for vaccine injection safety and effectiveness and economic animal food safety.

The invention provides a mucosal immune vaccine based on a porcine parainfluenza virus PIV5 carrier and application of the mucosal immune vaccine in immunization of sows and piglets, and belongs to the technical field of animal vaccines. According to the invention, on the basis of a porcine PIV5 reverse genetic operating system, the S gene of the porcine delta coronavirus (PDCoV) is inserted into a P-M gene spacer region of the PIV5 by using a P-M exogenous gene expression cassette of the PIV5, and a recombinant vaccine capable of expressing the PDCoV S is successfully rescued, and is named as JS17-PDCoV-S. A high-titer neutralizing antibody can be generated after the piglets are immunized by oral administration; after a sow orally takes the JS17-PDCoV-S vaccine, high-level serum IgG and mucous membrane sIgA antibodies can be generated. Meanwhile, the piglets are passively immunized by sucking milk, whole body and mucous membrane immune protection aiming at specific pathogens is provided for the piglets, early infection is effectively prevented, and the problem that IgG is easily degraded by digestive tracts of the piglets is solved.